Codeine in Sickle Cell Disease

Clinical Trial
Study Details
Enrollment
60
Interventions
Name
Codeine (30 mg)
Type
Drug
Phase
Phase 1
Phase 2
Status
COMPLETED
Study ID #
NCT00174538
Study Type
Interventional
Summary

The objective of this study is to determine if a subject's genetic make-up would affect the treatment response to codeine in subjects with sickle cell disease.

Study Overview
Conditions
Description

People with sickle cell disease require oral pain medications to manage an acute pain crisis. Sometimes these individuals fail to obtain adequate pain relief with the medications prescribed for outpatient use resulting in emergency room visits and hospital admissions. Subsequently, many patients are admitted to the hospital for pain management for a few days until the pain crisis resolves. The most common medications prescribed to sickle cell individuals for outpatient use include codeine and hydrocodone containing medications (i.e. Tylenol #3™, Vicodin™, Lortab™). These medications must be broken down in the body to make the active pain reliever (morphine or hydromorphone, respectively). Some individuals may not be able to break down these medications to the active pain reliever; therefore, these individuals will likely continue to experience pain unless they take other pain medications. We will determine whether genotype estimates the ability of CYP2D6 to break down codeine to the active pain reliever in individuals with sickle cell disease.

Contacts and Locations
Locations
Facility

University of Illinois Medical Center
Chicago, Illinois 60612
United States

GeoPoint
41.85003, -87.65005